Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 3, 2015, Pages 261-267

  Alexopoulos, Dimitrios ^a   Perperis, Angelos ^a   Koniari, Ioanna ^a   Karvounis, Haralambos ^b   Patsilinakos, Sotirios ^c   Ziakas, Antonios ^b   Barampoutis, Nikolaos ^a   Panagiotidis, Theofilos ^b   Akinosoglou, Karolina ^a   Hahalis, George ^a   Xanthopoulou, Ioanna ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Clopidogrel; Fibrinolysis; Platelet reactivity; Ticagrelor

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; GENITOURINARY BLEEDING; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BRUISING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; AGED; ANALOGS AND DERIVATIVES; BLEEDING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADENOSINE; AGED; BLOOD PLATELETS; FEMALE; FIBRINOLYSIS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84940437333     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1183-9     Document Type: Article

References (24)

1. Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621
2. Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189
3. Steg G, James SK, Atar D et al (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619
4. O’Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:e78–e140
5. Heestermans AA, van Werkum JW, Taubert D et al (2008) Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 122:776–781
6. Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585
7. Alexopoulos D, Xanthopoulou I, Gkizas V et al (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST elevation myocardial infarction. Circ Cardiovasc Interv 5:797–804
8. Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61:1601–1606
9. Wallentin L, Becker RC, Budaj A, for the PLATO Investigators et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057
10. Rasmanis G, Vesterqvist O, Green K et al (1992) Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br Heart J 68:374–376
11. Moser M, Nordt T, Peter K et al (1999) Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. Circulation 100:1858–1864
12. Gurbel PA, Serebruany VL, Shustov AR, for the GUSTO III Investigators et al (1998) Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 31:1466–1473
13. Diego A, de Prado AP, Cuellas C et al (2012) P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. Thromb Res 130:e31–e36
14. Price MJ, Angiolillo DJ, Teirstein PS et al (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 as-say: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124:1132–1137
15. Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747
16. Storey RF, Angiolillo DJ, Patil SB et al (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56:1456–1462
17. Alexopoulos D, Theodoropoulos KC, Stavrou EF et al (2012) Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther 26:393–400
18. Alexopoulos D, Gkizas V, Patsilinakos S et al (2013) Double vs standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol 62:940–941
19. Alexopoulos D, Makris G, Xanthopoulou I et al (2014) Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study. Circ Cardiovasc Interv 7:233–239
20. Alexopoulos D, Xanthopoulou I, Goudevenos J (2014) Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction. Am J Cardiol 113:2064–2069
21. Gurbel PA, Bliden KP, Butler K et al (2010) Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121:1188–1199
22. Alexopoulos D, Galati A, Xanthopoulou I et al (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60:193–199
23. Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723–731
24. Goudevenos J, Ntalas I, Xanthopoulou I et al (2014) Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis. J Thromb Thrombolysis 37:356–357